$3.66
-$0.06 (-1.61%)
$3.62Day Range$3.83
Key Statistics
Market Cap
$29.60M
Shares Outstanding
8.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 7, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$3.69
Day High
$3.83
Day Low
$3.62
Volume
96.5K
VWAP
$3.72
Prev Close
$3.72
Transactions
--
Acc. Volume
--
About Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Identifiers
- CIK
- 0001771885
- Composite FIGI
- BBG00L45SFK1
- Share Class FIGI
- BBG00L1C7XW0
- Ticker Root
- QNTM
About Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) Stock
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) closed the 2026-09-18 session at $3.66, down 1.61% versus the previous close (-0.06). The stock opened at $3.69 and traded between $3.62 and $3.83 during that session. Session trading volume was 96K shares. The volume-weighted average price (VWAP) is $3.72.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Quantum Biopharma Ltd. Class B Subordinate Voting Shares has a market capitalization of $29.6 million. QNTM is listed on the XNAS exchange. The company employs approximately 7 people. The recorded listing date is 2018-06-07.
On this page you can find market QNTM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.